The report "IVD Reagents Market by Type (Antibodies, Nucleic Acid Probes), technology (Hematology), Application (Genetic Testing, Autoimmune disease), Test Type (Laboratory Test, Point-of-care Tests), End User (Hospitals & Clinics) & Region - Global Forecast to 2029", is projected to reach 87.41 billion by 2029 from USD 60.45 billion in 2024, at a CAGR of 7.7% during the forecast period. The market growth is mainly due to growing burden of chronic diseases among aging population. In addition, increasing number of clinical laboratories providing in vitro diagnosis to offer growth opportunities for players operating in the IVD Reagents market during the forecast period. However, the stringent regulatory guidelines is expected to hamper the adoption of these products.
Browse 536 market data Tables and 59 Figures spread through 423 Pages and in-depth TOC on "IVD Reagents Market by Type (Antibodies, Nucleic Acid Probes), technology (Hematology), Application (Genetic Testing, Autoimmune disease), Test Type (Laboratory Test, Point-of-care Tests), End User (Hospitals & Clinics) & Region - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/ivd-reagents-market-131261429.html
In 2023, the Antibodies segment held the largest share of the IVD Reagents market, by type segment.
Based on type, the global IVD Reagents market is segmented into five categories namely, antibodies, antigen, purified proteins, and peptides, oligonucleotides, nucleic acid probes, and other IVD reagents. Antibodies has led the IVD Reagents market. This is primarily due to their characteristics and high adoption in both traditional laboratory-based tests and point-of-care (POC) testing devices. This segment is further divided into two subcategories monoclonal antibodies and polyclonal antibodies.
In 2023, the molecular diagnostics is the fastest growing segment of the IVD Reagents market, by technology.
Based on technology segment this is the fastest growing segment, the IVD Reagents market is segmented into categories namely, immunoassays, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, chromatography & mass spectrometry, and immunohistochemistry. During the forecast period, the molecular diagnostics segment is expected to observe highest growth rate in the IVD Reagents market. The dominance of this segment to drive this market is due to its expanding application in pharmacogenetics, personalized medicine, genetic testing and prenatal testing.
The Asia Pacific market is expected to witness the highest growth during the forecast period.
The global IVD Reagents market is divided into six key regions: North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries. The Asia Pacific is projected to register the highest CAGR of 10.0% in the IVD Reagents marketduring the forecast period. The large patient pool of chronic disorders such as diabetes, cancer, CVD and neurological disorders indicate a massive potential for the Asia Pacific IVD Reagents market. The North America holds the largest share in 2023 as this region has rising awareness of early disease detection.
Prominent players in the market include Danaher Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), BioMerieux (France), BD (US), Hologic, Inc. (US), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), Revvity (US), DiaSorin S.p.A (Italy), Grifols, S.A. (Spain), Werfen, S.A. (Spain), QuidelOrtho Corporation (US), Chembio Diagnostics, Inc. (US), Surmodics, Inc. (US), Merck KGaA (Germany), MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Tokyo), Canvax (Spain), Prestige Diagnostics (US), Adaltis S.r.l. (Italy), and Randox Laboratories Ltd. (UK)
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]